Trauma-Induced Phaeohyphomycosis in an Immunocompetent Host on Dupilumab.

dupilumab fungal diseases immunocompetent adults managing atopic dermatitis phaeohyphomycosis

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Dec 2023
Historique:
accepted: 22 12 2023
medline: 22 1 2024
pubmed: 22 1 2024
entrez: 22 1 2024
Statut: epublish

Résumé

Phaeohyphomycosis is a rare infection caused by dematiaceous fungi containing melanin in their cell wall. Patients are often immunocompromised, and cases seen in immunocompromised hosts have increased in recent years. Dupilumab, a monoclonal antibody against interleukin-4 (IL-4) and interleukin-13 (IL-13) used for the treatment of atopic dermatitis, has been linked to hypersensitivity reactions resulting in facial redness, and there is growing evidence that dupilumab may increase susceptibility to yeast infections as well. We present a case of trauma-induced cutaneous phaeohyphomycosis in an immunocompetent host on dupilumab. As dupilumab becomes more commonly encountered in practice, this case is meant to explore the potential relationship between dupilumab and predisposition to opportunistic fungal infections.

Identifiants

pubmed: 38249247
doi: 10.7759/cureus.50962
pmc: PMC10800155
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e50962

Informations de copyright

Copyright © 2023, Aggarwal et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Ishita Aggarwal (I)

Dermatology, University of Illinois College of Medicine, Chicago, USA.

David Arps (D)

Dermatopathology, Consolidated Pathology Consultants S.C., Libertyville, USA.

Edidiong Kaminska (E)

Dermatology, Kaminska Dermatology, Chicago, USA.

Classifications MeSH